Stay updated with breaking news from Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have received an average rating of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on […]
-- Enrollment in the phase 2 study of acazicolcept in systemic lupus erythematosus will be stopped to allow for early assessment of data -- -- Final analysis after last patient completes study...
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) insider James Paul Rickey sold 11,600 shares of the company’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $19.00, for a total transaction of $220,400.00. The sale was disclosed in a filing with the Securities & Exchange […]
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $19.41 and last traded at $19.41, with a volume of 39483 shares changing hands. The stock had previously closed at $18.92. Wall Street Analyst Weigh In A […]